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The clearance of protein-bound solutes by hemoﬁltration and
hemodiaﬁltration.
Background. Hemoﬁltration in the form of continuous ven
ovenous hemoﬁltration (CVVH) is increasingly used to treat
acute renal failure. Compared to hemodialysis, hemoﬁltration
provides high clearances for large solutes but its effect on
protein-bound solutes has been largely ignored.
Methods. Standard clinical systems were used to remove test
solutes from a reservoir containing artiﬁcial plasma. Clearances
of the protein-bound solutes phenol red (C PR ) and indican (C IN )
were compared to clearances of urea (C UREA ) during hemoﬁl
tration and hemodiaﬁltration. A mathematical model was de
veloped to predict clearances from values for plasma ﬂow Q p ,
dialysate ﬂow Q d , ultraﬁltration rate Q f , ﬁlter size and the ex
tent of solute binding to albumin.
Results. When hemoﬁltration was performed with Q p 150
mL/min and Q f 17 mL/min, clearance values were C PR 1.0 ±
0.1 mL/min; C IN 3.7 ± 0.5 mL/min; and C UREA 14 ± 1 mL/min.
The clearance of the protein-bound solutes was approximately
equal to the solute-free fraction multiplied by the ultraﬁltra
tion rate corrected for the effect of predilution. Addition of Q d
42 mL/min to provide HDF while Q p remained 150 mL/min
resulted in proportional increases in the clearance of proteinbound solutes and urea. In contrast, the clearance of proteinbound solutes relative to urea increased when hemodiaﬁltra
tion was performed using a larger ﬁlter and increasing Q d to
300 mL/min while Q p was lowered to 50 mL/min. The pattern
of observed results was accurately predicted by mathematical
modeling.
Conclusion. In vitro measurements and mathematical mod
eling indicate that CVVH provides very limited clearance of
protein-bound solutes. Continuous venous hemodiaﬁltration
(CVVHDF) increases the clearance of protein-bound solutes
relative to urea only when dialysate ﬂow rate and ﬁlter size are
increased above values now commonly employed.

.

Increasing molecular size limits solute transport by
diffusion more than solute transport by convection.
Henderson et al [1, 2] established that the clearance of
solutes with size ranging from about 500 to 15,000 D
can therefore be increased by employing hemoﬁltration
instead of hemodialysis. Clinical studies, however, have
so far failed to establish that hemoﬁltration is more bene
ﬁcial than hemodialysis over the long term. Hemodialysis
thus remains the predominant modality for end-stage re
nal disease (ESRD) treatment. Hemoﬁltration, however,
is increasingly employed in the treatment of acute renal
failure. In this setting, hemoﬁltration is usually prescribed
as continuous venovenous hemoﬁltration (CVVH) or
continuous venovenous hemodiaﬁltration (CVVHDF).
It has been suggested, though not proven, that clearance
of large solutes is particularly important when renal fail
ure develops in patients with sepsis, shock, or other condi
tions which precipitate multiorgan failure [3, 4]. Because
they are continuous therapies, CVVH and CVVHDF
may also facilitate control of extracellular ﬂuid volume
in patients with acute renal failure, who often receive
large amounts of intravenous ﬂuid and have low blood
pressure.
Remarkably, most studies of CVVH and CVVHDF
have failed to consider the effect of these treatments
on protein-bound solutes. The kidney clears many sub
stances which are bound to plasma proteins and in
particular to albumin. Such solutes accumulate in re
nal failure and there is increasing evidence that some
of them are toxic [5–8]. Protein binding limits con
vective as well as diffusive transport of solutes across
artiﬁcial kidney membranes. We have recently devel
oped a model which describes the clearance of proteinbound solutes during hemodialysis [9]. The current study
examined the clearance of protein-bound solutes dur
ing hemoﬁltration and hemodiaﬁltration. A mathemat
ical model was developed to describe solute clearances
and the predictions of this model were tested in vitro.

We found that small protein-bound solutes are poorly
cleared by hemoﬁltration. In particular, our results in
dicate that CVVH may clear protein-bound solutes less
effectively than intermittent hemodialysis and that the
clearance of such solutes can be increased by adding
dialysis to provide CVVHDF. Dialysate ﬂow rates much
higher than those conventionally used in CVVHDF, how
ever, are required to make the clearance of proteinbound solutes approach the clearance of unbound
solutes.

METHODS
Clearance measurements during vitro CVVH and
CVVHDF
CVVH. Clearances of phenol red, indican, urea, and
creatinine were measured during CVVH in vitro. Fluid
representing a patient’s plasma was placed in a continu
ously stirred 1.0 L reservoir and CVVH was performed
using a Prisma system (Gambro, Lakewood, CO, USA).
The reservoir ﬂuid contained bovine albumin (Sigma
A-7906) (Sigma Chemical Co., St. Louis, MO, USA) at
4.0 g/dL and had electrolyte concentrations which ap
proximated sodium 149 mEq/L, potassium 4.0 mEq/L,
magnesium 2.0 mEq/L, calcium 2.5 mEq/L, and PO 4 47.5
mg/dL with the pH adjusted to 7.4. Reagent phenol red,
indican, urea, and creatinine were added to the reservoir
to provide concentrations of approximately 3.0 mg/dL,
2.0 mg/dL, 120 mg/dL, and 12.0 mg/dL, respectively, at
the beginning of each CVVH run. Replacement ﬂuid con
tained electrolytes in the same concentrations as reser
voir ﬂuid but no albumin or test solutes. CVVH was
performed over 150 minutes (four runs) in the predilu
tion mode using a Prisma M60 Set which includes a 0.6
m2 kidney composed of AN69 hollow ﬁbers with wall
thickness 50 lm. The “plasma” (reservoir ﬂuid) ﬂow rate
set at 150 mL/min and ultraﬁltration and replacement
ﬂuid ﬂow rates set equal at 16.7 mL/min. The ultraﬁltrate
volume was measured at the end of each experiment.
The free solute fraction was calculated as the average of
the solute concentration in the efﬂuent line divided by the
solute concentration in the reservoir in samples obtained
at 10 and 150 minutes. Additional reservoir ﬂuid samples
were obtained at 0, 10, 30, 60, 90, and 120 minutes for
clearance calculations.
CVVHDF. CVVHDF in vitro was ﬁrst performed us
ing the Prisma system with the same kidney and with the
same reservoir and replacement ﬂuids as used in CVVH
experiments. The dialysate had the same composition as
the replacement ﬂuid. The dialysate ﬂow rate was set
at 41.7 mL/min while the plasma ﬂow was again set at
150 mL/min and the ultraﬁltration and replacement ﬂow
rates at 16.7 mL/min. The reservoir volume was increased

to 2.0 L and CVVHDF was performed over 75 minutes
(four runs). The total volume of ultraﬁltrate combined
with dialysate was measured at the end of each experi
ment. Batches of albumin-containing ﬂuid were puriﬁed
by dialysis for 2 hours before test solutes were added for
clearance experiments. This was done to reduce possi
ble interference with solute binding to albumin by con
taminants in the reagent albumin. The free fraction of
each solute was calculated as the average of measure
ments made at 5 and 75 minutes. Microcon YM-30 tubes
(Millipore, Billerica, MA, USA) were used to obtain ul
traﬁltrate from reservoir ﬂuid for these measurements,
since ultraﬁltrate in the efﬂuent line was mixed with
dialysate. Additional reservoir ﬂuid samples were ob
tained at 0, 5, 15, 30, 45, 60, and 75 minutes for clearance
calculations.
To test the effects of a higher dialysate ﬂow and larger
kidney size, in vitro CVVHDF was performed using a
Fresenius D machine and F6 kidney (Fresenius, Gurnee,
IL, USA). The F6 kidney provides a 1.3 m2 surface area
composed of polysulfone hollow ﬁbers with wall thick
ness 40 lm. As such, it provides K o A values for vari
ous solutes which are approximately threefold greater
than those provided by the Prisma M60 set, as further
described in the results below. The dialysate ﬂow rate
for CVVHDF experiments performed with the F6 was
set at 300 mL/min while the plasma ﬂow was set at
55 mL/min and the ultraﬁltration and ﬂuid replacement
rates were again set at 16.7 mL/min. CVVHDF was per
formed over 75 minutes (four runs). Solute free frac
tions were measured as described above and samples
were collected at 0, 15, 30, 45, 60, and 75 for clearance
calculations.
Chemical assays and clearance calculations. Creati
nine was measured with a Beckman Creatinine Ana
lyzer 2 and urea was measured using a commercial kit
(1770-50) (ThermoDMA, Arlington, TX, USA). Indican
was measured by high-performance liquid chromatog
raphy (HPLC) (Agilent 1100) (Agilent, Palo Alto, CA,
USA). Plasma samples were deproteinized by addition of
900 lL of methanol to 300 lL of plasma. This method
which is derived from that of Lagana et al [10] provided
indican recovery of 102 ± 2% and phenol red recovery of
108 ± 7% (four runs at 1.0 mg/dL and 1.5 mg/dL, respec
tively). Samples of the resulting supernatant were assayed
by ﬂuorescence detection (excitation 250 nm, emission
410 nm) following processing on a C18 column using gra
dients of 50 mmol/L ammonium formate and methanol
as described by Lesaffer et al [11]. For CVVH and
CVVHDF, phenol red was assayed using a method mod
iﬁed from Hirata-Dulas et al [12] as previously described
[9]. For CVVHDF with higher dialysate ﬂow, phenol red
was measured by HPLC using the same protocol as for
indoxyl sulfate but employing ultraviolet absorption at

433 nm rather than ﬂuorescence for detection. Clear
ance values were calculated from the best ﬁt slope of log
values for concentrations and from measured reservoir
volume corrected for the volume of samples removed.
Clearance values for various treatments were com
pared by one-way analysis of variance (ANOVA) with
post hoc least signiﬁcant difference testing for multiple
comparisons.
Values for K o A for the M60 and F6 ﬁlters were deter
mined in separate experiments in which dialysis was per
formed without albumin in the reservoir. In these experi
ments (three for each ﬁlter), the Fresenius D machine was
used with the ultraﬁltration rate set at zero. For the M60
ﬁlter, Q p was set at 200 mL/min and Q d at 300 mL/min
and for the F6 ﬁlter, Q p was set at 300 mL/min and Q d
at 500 mL/min. Clearances for urea, creatinine, indican,
and phenol red were measured as the average of the arte
rial venous (A-V) extraction multiplied by Q p measured
four times over 30 minutes during each experiment. K o A
values for each solute were then obtained from measured
values for clearance, Q p , and Q d using the equation de
scribed by Michaels [13].
Modeling the effect of protein binding on solute clearance
Hemoﬁltration. The ﬂux of a solute which is not
protein-bound during hemoﬁltration can be expressed as:
Js = Jv · (1 − r) · C p · c

(equation 1)

where J v is the volume ﬂux, r is the reﬂection coefﬁcient
for the solute, C p is the solute concentration in plasma,
and c is a factor which relates the solute concentration in
plasma to the solute concentration in plasma water C pw :

where f is the fraction of solute which is not bound to
proteins. Solute ﬂux can then be expressed as:
Js = Jv · f · C p · c

(equation 5)

When hemoﬁltration is performed with replacement
ﬂuid added to the plasma before it enters the kidney,
values for f , C p , and c must be corrected for the effects
of this “predilution.” The corrected solute concentration
C p c is:
C cp =

C p · Qp
Qp + Qr

(equation 6)

and the corrected plasma protein concentration h c used
to correct c is
hpc =

hp · Qp
Qp + Qr

(equation 7)

where Q p is the plasma ﬂow rate and Q r is the replace
ment ﬂuid addition rate. The effect of predilution on f is
less obvious but while predilution reduces the total solute
concentration and protein concentration in proportion, it
tends to increase the free fraction of a protein-bound so
lute. The magnitude of this effect can be calculated assum
ing that solute binding to albumin (or any other binding
protein) is described by an association constant K A such
that:
C p − C pf
KA =
(equation 8)
C pf · (Calb − C p + C pf )
This being the case, f can be expressed as:
f =

1
(equation 9)
1 + (Calb − C p + C pf ) · KA

where h is the plasma protein concentration in g/dL
multiplied by 0.011 [14]. To model the clearance of
protein-bound solutes, we introduced two modiﬁcations
in equation 1. First, the model was limited to small solutes
for which r is effectively zero. For modern membranes,
this includes solutes with size less than 2000 D, and thus
includes almost all the protein-bound solutes which have
been shown to accumulate in uremia [7, 15]. Second, it
was assumed that only the portion of a solute not bound
to protein is ﬁltered. The free solute concentration C pf
available for ﬁltration is thus represented by the follow
ing:

and the value f c corrected for predilution is then given by
equation 10 (see Appendix).
The magnitude of this correction, which is hard to ap
preciate by inspection of equation 10, is illustrated in Fig
ure 1. It should be noted that the application of equations
8 to 10 to dialysis systems is based on the assumption that
solute binding to protein is rapidly reversible. In using
equation 10 to correct f for the effect of predilution, we
assume that solute can dissociate from protein in the time
it takes for plasma to ﬂow to the kidney from the point in
the circuit where predilution ﬂuid is added. As revealed
by Figure 1, the magnitude of this correction is small for
the Q r /Q p ratios used in our experiments.
During hemoﬁltration, the free solute concentration
does not change as plasma passes along the kidney. Equa
tion 5 therefore not only describes local values for ﬂux, ex
pressed as solute transport and ﬂuid ﬂow per unit length
along the kidney, but also can be used to calculate the
total transport. Solute clearance is then given by:

C pf = f · C p .

Cl = Jv · f · c

C pw = c · C p

(equation 2)

This correction factor can be estimated as:
c =

1
1−h

(equation 3)

(equation 4)

(equation 11)

1

where k is the membrane permeability, here expressed
per unit length along the kidney, and
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where Pe, the Peclet number, is a dimensionless quan
tity which represents the ratio of convective to diffusive
transport and is given by:
(1 − r) · Jv
k

Pe =

Fig. 1. The predicted effect of predilution with a replacement ﬂuid ﬂow
rate (Q r ) on the free fraction (f c ) of protein-bound solutes. Curves are
drawn for solutes whose free fractions are 0.10, 0.30, and 0.50 in plasma
before the addition of replacement ﬂuid. f c increases as Q r increases
relative to Q p . In clinical practice with Q r less than Q p , the effect is
modest but still large enough so that predilution causes less reduction in
the clearance of protein-bound solutes than in the clearance of unbound
solutes.

with appropriate substitution of f c and cc if predilution is
employed.
Hemodiaﬁltration. In hemodiaﬁltration, solute con
centrations vary along the length of the kidney and local
ﬂuxes must be integrated to obtain total ﬂuxes. For these
calculations, the kidney was considered to have a dimen
sionless length of unity (0 ≤ x ≤ 1) with the plasma (or
reservoir ﬂuid) inlet and dialysate outlet at x = 0 and
the plasma outlet and dialysate inlet at x = 1, provid
ing countercurrent ﬂow. The transfer of solute along an
inﬁnitesimal length of the kidney during hemoﬁltration
with countercurrent ﬂow dialysis must then satisfy the
conservation of mass:
−Js · dx = d (QpC p ) = d (Qd Cd )
(equation 12)

(equation 16)

(equation 17)

The same modiﬁcations used in the case of pure
hemoﬁltration were again used to adapt these equations
to describe the ﬂux of protein-bound solutes. The model
was restricted to small solutes for which sigma is effec
tively equal to zero and the effective solute concentration
on the plasma side was assumed to be the unbound solute
concentration:
C pf = f · C p

(equation 18)

When convection and diffusion are combined, f will
vary along the length of the ﬁlter. The local value for f
can be expressed as:

fx =

C p,x − Calb,x −

1
KA

+

(
Calb,x − C p,x +

1
KA

)2

+

4C p,x
KA

2C p,x
(equation 19)

where K A is the association constant described in equa
tion 8 and where C p,x is the local solute concentration
and C alb,x is the local albumin concentration which is in
turn given by
Calb,x =

Calb,0 · Qp,0
fx
Qp,0 − Jv · dx

(equation 20)

0

and the transfer of ﬂuid must satisfy the conservation of
volume:
−Jv · dx = dQp = dQd

(equation 13)

where Q p is the volumetric ﬂow of plasma, Q d is the
volumetric ﬂow of dialysate, C p is the solute concentra
tion in the plasma, and C d is the solute concentration in
the dialysate. The ﬂux of an unbound solute being trans
ported by both diffusion and convection can further be
described by the equations 14 to 17 as developed by Vil
larroel, Klein, and Holland [16] and further elaborated
by Waniewski et al [17]:
Js = −k · (C pw − Cd ) + Jv · (1 − r) · C̄ (equation 14)

In applying equations 8 and 19, we again assume that
solute binding to protein is rapidly reversible. Speciﬁcally,
we assume that the time required for solute to dissoci
ate from albumin is short in comparison to the time re
quired for plasma to transit the artiﬁcial kidney. In the cur
rent study, the plasma transit time for experiments with
the M60 kidney was approximately 20 seconds and the
plasma transit time for experiments with the F6 kidney
was approximately 60 seconds. We do not know the rate
constants for the dissociation of phenol red and indican
from albumin. Bilirubin, however, which is much more
tightly bound, can dissociate from plasma albumin in a
fraction of a second [18, 19]. Moreover, the blood transit
time through the native kidney, which effectively removes

many protein bound solutes, is less than 5 seconds. We
therefore modeled protein bound solute clearance based
on the assumption of rapid dissociation. To the extent
that this assumption is untrue, the real clearance of pro
tein bound solutes will be less than that predicted by the
model. In the extreme case where no solute dissociates
from albumin as plasma transits the kidney, the clearance
of a protein bound solute would be equal to the clear
ance of an unbound solute of the same size multiplied
by f .
To determine solute transport using the above equa
tions, we must ﬁrst specify the proﬁle of ﬂuid transport
along the kidney. The total ﬂuid transport must add up to
the ultraﬁltration rate so that:

Table 1. Solute clearances during continuous venovenous
hemoﬁltration (CVVH)
Solute

Free fraction
%

Measured
clearance mL/min

Predicted
clearance mL/min

Urea
Creatinine
Indican
Phenol red

100 ± 8
100 ± 3
25 ± 3a
8.1 ± 1.0a,b

14 ± 1
14 ± 1
3.7 ± 0.5a
1.0 ± 0.1a,b

16 ± 1
16 ± 1
4.3 ± 0.6a
1.4 ± 0.2a,b

Values are mean ± SD. Solute free fractions were assessed after predilution
and clearance values were obtained with Q p ≈ 150 mL/min, Q r ≈ 17 mL/min,
and Q f ≈ 17 mL/mn.
a <
P 0.05 vs. value for urea; b P < 0.05 vs value for indican.

(equation 25)

analytic solution which described the transport of
protein-bound solutes. We are thus unable to provide a
formula for clearance during CVVHDF analogous to the
formula provided by equation 11 for CVVH or by the
equations of Michaels [13] for hemodialysis using coun
tercurrent ﬂow.
Input values of the model described above include the
transmembrane pressures fP 0 and fP 1 which are not
routinely measured in clinical practice. In modeling clin
ical CVVHDF, however, the simplifying assumption of
a uniform value for fP along the length of the ﬁlter
can be employed without introducing signiﬁcant error.
For instance, in a separate experiment in which an ad
ditional pressure transducer was added to the clinical
system, we found that when CVVHDF was performed
with the M60 at the ﬂows used in this study, fP 0 was
88 mm Hg and fP 1 was 62 mm Hg. Use of a constant
fP value instead of these measured values produced
changes in predicted solute clearance values of less than
1%. When CVVHDF was performed with the F6 and the
ﬂows used in this study, measured values for fP 0 and
fP 1 were 17 mm Hg and was 15 mm Hg. Use of con
stant fP values instead of these measured values again
produced changes in predicted solute clearance values of
less than 1%. In general, variation of fP along the ﬁl
ter will affect clearances only when rapid ultraﬁltration
is combined with efﬁcient dialysis, and the effect of fP
variation on clearance will diminish as solute binding in
creases. It should be noted that in such cases the pressure
drop along the kidney may not be linear, as ultraﬁltration
simultaneously decreases blood ﬂow and increases blood
viscosity.

are substituted for Q p,0 , C p,0 and C alb,0 . For the present
study, K A was calculated from measured values for f , C p ,
and C alb using equations 4 and 8. Predicted values for so
lute transport were obtained by solving the above equa
tions using MATLAB (MathWorks, Natick, MA, USA).
It should be noted that for the case of unbound solutes
(K A = 0) and linear variation of J v along the length
of the ﬁlter, Waniewski et al [17] obtained an analytic
solution to these equations. But we did not obtain an

RESULTS
Clearances measured during CVVH in vitro are sum
marized in Table 1. Clearance values for the unbound
solutes urea and creatinine averaged 14 ± 1 mL/min.
Clearance values for the protein bound solutes were
much lower, averaging 3.7 ± 0.5 mL/min for indican and
1.0 ± 0.1 mL/min for phenol red. The measured values

1

Qf =

Jv · dx

(equation 21)

0

For the current model, we assumed that the transmembrane hydraulic pressure difference changes linearly
along the kidney and that J v is proportional to the local
value for transmembrane hydraulic pressure, fP x . In this
case, the local value for J v is:
[
]
fP0 · (1 − x) + fP1 · x
Jv,x = 2 · Q f ·
fP0 − fP1
(equation 22)
where fP 0 is the transmembrane pressure at the plasma
inlet end of the ﬁlter and fP 1 is the transmembrane pres
sure at the plasma outlet end of the ﬁlter.
Using values for f x provided by equations 19 to 22,
equations 12 to 15 can be solved to yield total solute trans
port in terms of the boundary variables Q p,0 , C p,0 , C alb,0 ,
Q d,1 , and Q f and the constants K A and K o A. When predi
lution is employed, the value Q r is also speciﬁed and the
values:
C p,0 · Qp,0
C cp,0 =
(equation 23)
Qp,0 + Qr
c
Calb,0
=

Calb,0 · Qp,0
Qp,0 + Qr

(equation 24)

and
Qcp,0 = Qp,0 + Qr

Table 2. Solute clearances during continous venovenous
hemodiaﬁltration (CVVHDF) with dialysate ﬂow less than plasma
ﬂow
Free Fraction
%

Measured
clearance mL/min

Predicted
clearance mL/min

Urea
Creatinine
Indican
Phenol red

100 ± 1
101 ± 1
18 ± 5b
6.4 ± 0.9b,c

45 ± 2a
42 ± 3a
10 ± 2a,b
2.7 ± 0.3a,b,c

52 ± 2
51 ± 2
9 ± 2b
2.9 ± 0.4b,c

Values are mean ± SD. Solute free fractions were assessed after predilution
and clearance values were obtained using an M60 ﬁlter with Q p ≈ 150 mL/min,
Q d ≈ 42 mL/min, Q r ≈ 17 mL/min, and Q f ≈ 17 mL/mn.
a
P < 0.05 vs measured clearance during in vitro continuous venovenous
hyperﬁltration (CVVH).
b <
P 0.05 vs. value for urea.
c <
P 0.05 vs. value for indican.
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Fig. 3. The predicted effect of K o A on solute clearances during con
tinous venovenous hemodiaﬁltration (CVVHDF) with Qd < Q p . The
conditions represented are similar to those of our experiments with
Q d ≈ 42 mL/min and Q f ≈ 17 mL/min except that the small effect
of predilution is omitted for simplicity. As K o A increases, clearance of
an unbound solute (green line) approaches the theoretic maximum of
Q d plus Q f and the clearance of a solute which is 90% protein bound
(purple line) approaches the theoretic maximum of 10% of Q d plus Q f .
Near maximal clearance values are obtained with small ﬁlters as long
as Q d is low.
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Fig. 2. Solute concentrations along the length of a dialyzer during con
tinous venovenous hemodiaﬁltration (CVVHDF) with Qd < Q p . In
each panel, dialyzer length is on the horizontal axis with the plasma in
let and dialysate plus ultraﬁltrate outlet at the left (x = 0) and the plasma
outlet and dialysate inlet at the right (x = 1). Solute concentration is
on the vertical axis. The total plasma solute concentration (red line) is
set equal to 1.0 prior to predilution and the dialysate solute concen
tration (blue line) is set equal to 0.0 at the dialysate inlet. When there
is protein binding, the concentration of unbound solute is depicted by
the broken red line. The gradient driving diffusion is indicated by the
shaded area. The top panel depicts the clearance of an unbound solute
during CVVHDF performed with Q p ≈ 150 mL/min, Q f ≈ 17 mL/min,
and Q r ≈ 17 mL/min predilution, Q d ≈ 42 mL/min, and K o A ≈ 150
mL/min. The solute concentration in the slowly ﬂowing dialysate plus
ultraﬁltrate stream approaches the solute concentration in the plasma
entering the ﬁlter and the clearance is 49 mL/min. This is close to the
theoretic maximum of 53 mL/min imposed by the sum of Q d and Q f
corrected for the effect of predilution. The bottom panel depicts the
clearance of a solute which is 90% bound to plasma protein. The so
lute concentration in the dialysate plus ultraﬁltrate stream is limited
by the free solute concentration in the plasma entering the ﬁlter and
the clearance is 5.5 mL/min. The value is slightly higher than 10% of
the unbound solute clearance because predilution increases the solute
free fraction from 10% to 11%. The relative magnitude of the solute
clearances is reﬂected by the size of the arrows on the left of the ﬁgure.

were close to the values predicted by equation 11. Essen
tially, the predicted clearance rate for unbound solutes is
the ultraﬁltration rate corrected for the effect of predi
lution. The predicted clearance rate for bound solutes
is obtained by multiplying this value by the plasma free
fraction, with a further correction for the effect of predi
lution on the free fraction as described in the Methods
section (equations 10 and 11) and Figure 1.
Clearances measured during CVVHDF performed
with the dialysate ﬂow lower than the plasma ﬂow are
summarized in Table 2. These experiments were per
formed using the maximal dialysate ﬂow rate attainable
with a commonly used CVVHDF system. The clearance
rates of all solutes were signiﬁcantly increased in com
parison with values obtained during CVVH alone. Mea
sured clearance values for the unbound solutes urea and
creatinine averaged 45 ± 2 mL/min and 42 ± 3 mL/min,
respectively. Clearance values for the bound solutes also
increased but remained much lower than those for the un
bound solutes. Overall, the proportional increase in clear
ance observed with the addition of dialysate to CVVH
was similar for the unbound and bound solutes, and av
eraged approximately threefold.
The ﬁnding that superimposing dialysis with Q d < Q p
on hemoﬁltration increases the clearances of unbound
and bound solutes in similar proportion is in accord
with the predictions of the model. With dialysate ﬂow
much lower than plasma ﬂow and with adequate mem
brane permeability, the model predicts that the solute
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Fig. 4. Solute concentrations along the length of a dialyzer during con
tinuous venovenous hemodiaﬁltration (CVVHDF) with Qd > Q p . The
plasma total solute concentration (red line) and free solute concentra
tion (broken red line) and dialysate solute concentration (blue line)
are depicted as in Figure 2. The top panel depicts the clearance of an
unbound solute in CVVHDF performed with Q p ≈ 50 mL/min, Q f ≈
17 mL/min, and Q r ≈ 17 mL/min predilution, Q d ≈ 300 mL/min, and
K o A ≈ 600 mL/min. Solute is rapidly removed from the plasma and the
calculated clearance is 50 mL/min, which is the limiting value imposed
by the plasma ﬂow. The bottom panel depicts the clearance of a solute
which is 90% bound to plasma protein while other parameters remain
the same. The gradient driving solute diffusion into the dialysate plus
ultraﬁltrate stream is reduced by protein binding. Transport continues
along the length of the dialyzer because the increased dialysate ﬂow
keeps the level in the dialysate plus ultraﬁltrate compartment lower
than the free level in the plasma. The bound solute clearance of 23
mL/min is almost half the clearance of the unbound solute, and could
be made to approach even closer to the plasma ﬂow by further increas
ing Q d and K o A.

concentrations in the mix of dialysate and ultraﬁltrate
leaving the kidney will be nearly equal to the free solute
concentrations in the plasma entering the kidney, as il
lustrated in Figure 2. The clearance of each solute will
thus approach the sum of the dialysate ﬂow and ultraﬁl
tration rates multiplied by the free solute concentration
at the kidney inlet. Solute clearances will fall below this
theoretic maximum if the kidney has a low mass transfer
area coefﬁcient, as shown in Figure 3. Dialysis experi
ments performed without albumin yielded K o A values
for the M60 set of 186 ± 12 for urea, 106 ± 6 for crea
tinine, 108 ± 10 for indican, and 61 ± 6 for phenol red.
In our CVVHDF experiments with Q d < Q p , values for
K o A were thus greater than Q d . When this is the case,
as further shown in Figure 3, an increase in kidney size
would not signiﬁcantly increase solute clearances. When
Q d < Q p , changes in Q p will likewise have little effect on
clearance. Our model predicts, for example, that reducing

0

4

8

12
Qd/Qp

16

20

Fig. 5. The predicted effect of increasing Q d and K o A on solute clear
ances during continuous venovenous hemodiaﬁltration (CVVHDF).
The curves illustrate the clearance of an unbound solute (green line)
and a solute which is 90% protein bound (purple line) as Q d and K o A
are increased with K o A equal to twice Q d at every point. The clearance
of both unbound and bound solutes is limited by the plasma ﬂow rate,
Q p . But raising solute clearance to any desired fraction of Q p requires
much larger values of Q d and K o A when the solute is protein bound
than when the solute is unbound. The ultraﬁltration rate Q f , which is set
at one third of Q p in this ﬁgure, has a signiﬁcant effect on the clearance
of small solutes only when Q d and K o A are relatively low.

Q p from 150 to 75 mL/min while Q d is maintained at 42
mL/min would reduce the clearance of urea by less than
15% and the clearance of indican and phenol red by less
than 5%.
Having found that superimposing dialysis with Q d <
Q p on hemoﬁltration increases the clearance of bound
and unbound solutes in nearly equal proportion, we
sought a means to preferentially increase the clearance
of bound solutes. The model predicts that this can be ac
complished by increasing the dialysate ﬂow above the
plasma ﬂow as long as membrane permeability is ade
quate. The results of in vitro CVVHDF experiments per
formed to test this prediction are summarized in Table
3. The measured clearances of urea and creatinine, 52
± 3 mL/min and 54 ± 3 mL/min, respectively, were only
slightly greater than observed in the previous experiment.
But the measured clearances of indican and phenol red,
31 ± 2 mL/min and 10.2 ± 0.4 mL/min, respectively, were
increased threefold. The ratio of bound to unbound so
lute clearances was thus greatly increased, in accord with
the predictions of the model.
The solute concentration proﬁles associated with the
increased clearance of bound solute when Q d is greater
than Q p are depicted in Figure 4. Increasing the dialysate
ﬂow above the plasma ﬂow reduces solute concentrations
in the dialysate plus ultraﬁltrate compartment. The un
bound solute diffuses readily into the large quantity of
dialysate plus ultraﬁltrate, and its concentration rapidly
approaches zero as the plasma ﬂows through the kid
ney. Thus, for the unbound solute, transport is practi
cally complete in the early part of the kidney and the

Table 3. Solute clearances during continous venovenous
hemodiaﬁltration (CVVHDF) with plasma ﬂow less than dialysate
ﬂow
Solute
Urea
Creatinine
Indican
Phenol red

Free
fraction %

Measured
clearance mL/min

Predicted
clearance mL/min

105 ± 1
99 ± 6
16 ± 1b
5.8 ± 0.7b,c

52 ± 3a
54 ± 3a
31 ± 2a,b
10.2 ± 0.4a,b,c

53 ± 1
53 ± 1
27 ± 1b
9.0 ± 0.9b,c

Values are mean ± SD. Solute free fractions were assessed after predilution
and clearance values were obtained using an F6 ﬁlter with Q p ≈ 55 mL/min, Q d
≈ 300 mL/min, Q r ≈ 17 mL/min, and Q f ≈ 17 mL/min.
a
P < 0.05 vs. measured clearance during in vitro continous venovenous
hemoﬁltration (CVVH) and CVVHDF with dialysate ﬂow less than plasma ﬂow.
b <
P 0.05 vs. value for urea.
c <
P 0.05 vs. value for indican.

clearance approaches the plasma ﬂow rate. The concen
tration proﬁle for the protein-bound solute is different.
The gradient driving diffusion is reduced by protein bind
ing even though the high dialysate ﬂow keeps the solute
concentration in the combined dialysate plus ultraﬁltrate
low. So the rate of solute transfer in the early part of the
kidney is much lower than for the unbound solute. But
as free solute diffuses through the membrane, bound so
lute dissociates from protein, replenishing the low free so
lute concentration available for diffusion and convection.
The total concentration and the free concentration of the
protein-bound solute fall gradually together as transport
continues along the length of the kidney. In contrast to
the result obtained when dialysate ﬂow is only a fraction
of plasma ﬂow, the clearance of the protein-bound solute
can now exceed the clearance of the unbound solute mul
tiplied by the free fraction of the bound solute. Again, we
are assuming that the time required for solute to disso
ciate from the binding protein is short compared to the
transit time of plasma through the kidney.
To obtain a high relative clearance of protein-bound
solutes during CVVHDF requires an increase in K o A as
well as in Q d . Dialysis experiments performed without
albumin yielded K o A values for the F6 dialyzer of 549 ±
30 mL/min for urea, 353 ± 24 mL/min for creatinine, 371
± 17 mL/min for indican, and 221 ± 13 mL/min for phenol
red. In our CVVHDF experiments with Q d > Q p , esti
mated K o As were thus of approximately the same mag
nitude as Q d . Theoretically, as long as K o A is adequate,
the clearance of even a tightly bound solute can be made
to increase arbitrarily close to the limiting value imposed
by the plasma ﬂow, as illustrated in Figure 5. The ﬁgure
shows modeled clearance values for an unbound solute
and a protein-bound solute as Q d is increased from zero
(pure ultraﬁltration) to greatly exceed Q p while the Q f
remains constant and K o A increases with Q d . For an un
bound solute, the clearance at Q d = 0 mL/min is equal
to Q f , and the clearance at low values for Q d is close to
the sum of Q f and Q d , as has been previously described
[20–22]. As Q f is increased, the clearance of the unbound

solute falls below the sum of Q f and Q d but still rapidly
rises to approach Q p . The clearance proﬁle for a proteinbound solute is much different. For low values of Q d , the
clearance is close to the clearance of the unbound so
lute multiplied by the fraction of the bound solute which
is free in plasma. As Q d increases, the clearance of the
bound solute increases more gradually than the clearance
of an unbound solute, but keeps rising after the clearance
of the unbound solute has reached the limiting value of
Q p . It should be noted that with high dialysate ﬂow, the
transport of small solutes is accomplished largely by dif
fusion, and turning ultraﬁltration on and off has only a
minor effect on solute clearance.
DISCUSSION
The ﬁrst aim of this study was to assess the clearance of
protein-bound small solutes during hemoﬁltration. Re
sults showed that for a given protein-bound solute, the
clearance is approximately the ultraﬁltration rate mul
tiplied by the free solute fraction, corrected as neces
sary for the effects of predilution on solute concentration.
Protein-bound solutes are thus poorly cleared by conven
tional CVVH. For instance, with an ultraﬁltration rate of
30 mL/min, the predicted clearance of a solute which is
90% protein bound is only 3 mL/min using postdilution
and slightly less than 3 mL/min using predilution.
The limitation imposed by protein-binding on solute
clearance during hemoﬁltration is not hard to understand,
but has received little attention. Hemoﬁltration was
developed to improve the clearance of solutes whose
diffusive transport during dialysis is limited by size [2].
Advocates of hemoﬁltration suggest that it is “more phys
iologic” than dialysis because it removes solutes by a pro
cess analogous to glomerular ﬁltration [23, 24]. In this
view, the infusion of replacement ﬂuid takes the place of
tubular reabsorptive function. But the absence of tubu
lar secretory function, by which the normal kidney clears
protein-bound solutes, is ignored.
The second aim of this study was to assess the clear
ance of protein-bound small solutes during hemodiaﬁl
tration when dialysis is superimposed on hemoﬁltration.
We found that as long as dialysate ﬂow is low compared to
plasma ﬂow, the superimposition of dialysis on hemoﬁl
tration increases the clearances of unbound and proteinbound solutes in proportion, with the clearance rate for a
given solute being approximately the free solute fraction
multiplied by the sum of the ultraﬁltration and dialysate
ﬂow rates. The hemodiaﬁltration prescriptions now com
monly employed in the treatment of acute renal failure
thus do not provide greater relative clearance of proteinbound solutes than pure hemoﬁltration.
The ﬁnal aim of this study was to identify means by
which the clearance of protein- bound solutes can be
increased relative to the clearance of unbound solutes.

Table 4. Modeled solute clearances during renal replacement therapy
Modality
Q b mL/min
Q f mL/min
Q r mL/min
Q d mL/min
K o A urea mL/min
Cl urea mL/min
Cl 90%−bound mL/min

Conventional
hemodialysis

CVVH
low Q f

CVVH
high Q f

CVVHDF
low Q d

CVVHDF
high Q d

Low efﬁciency
hemodialysis

Low efﬁciency
hemodialysis

350
24
0
600
800
270
46

150
20
18
0
200
19
2.0

150
40
38
0
200
34
4.2

150
20
18
20
200
38
4.2

50
20
18
300
600
45
21

200
4
0
100
600
100
11

100
4
0
200
600
90
20

Abbreviations are: CVVH, continuous venovenous hemoﬁltration; CVVHDF, continuous venovenous hemodiaﬁltraton. Modeled clearance values for urea (Cl urea )
and a hypothetical solute of the same size which is 90% protein-bound (Cl 90%−bound ) during renal replacement therapy. The various prescriptions would provide the
same net ultraﬁltration if conventional hemodialysis was applied every other day and the other treatments were provided daily. The hematocrit was assumed to be 33%
in each case.

We found that this can be accomplished by increasing
the dialysate ﬂow rate while restricting the plasma ﬂow
rate during hemodiaﬁltration. Indeed, by adequately in
creasing the dialysate ﬂow, the clearance of small proteinbound solutes can be increased arbitrarily close to the
clearance of small unbound solutes as long as kidney size
is adequate. It should be noted that in current practice,
when the dialysate ﬂow exceeds the plasma ﬂow, it also
exceeds the ultraﬁltration rate. In this setting, the contri
bution of ultraﬁltration to the transport of protein-bound
solutes is relatively small, and the clearance of proteinbound solutes is only slightly higher than that achieved by
dialysis alone. The clearance of large solutes, in contrast,
will still depend heavily on ultraﬁltration.
The current model also reveals one alternate theoret
ical means to increase the clearance of protein-bound
solutes. As shown in Figure 1, if we assume solutes can
rapidly dissociate from their binding proteins, the bound
fractions will fall as the rate of predilution rises, and solute
clearances can be increased during pure ultraﬁltration by
using predilution and increasing the replacement and ul
traﬁltration rates to greatly exceed the plasma ﬂow. Be
cause replacement ﬂuid is more expensive than dialysate,
however, this treatment would not be cost effective.
Solute clearances have the same dependence on
plasma and dialysate ﬂows during intermittent and
continuous treatment. But hemoﬁltration and hemodi
aﬁltration are most often prescribed continuously for
the treatment of acute renal failure. Currently employed
CVVH and CVVHDF regimens provide greater clear
ances of large solutes than intermittent hemodialysis
while providing equal or greater clearances of urea, de
pending on the exact prescription [21, 25–27]. The current
study suggests that in contrast, CVVH and CVVHDF
may provide relatively low clearances of protein-bound
solutes, as summarized in Table 4. The table presents
clearance values for urea and a hypothetical solute PBS
which is 90% bound to albumin. The clearance values
have been calculated using the model described in the
current study with the urea clearances corrected for the
transport of urea out of red cells as described by Depner

[28]. Intermittent hemodialysis with Q b ≈ 350 mL/min
and Q d ≈ 600 mL/min is predicted to provide a PBS
clearance of ≈ 42 mL/min while CVVH with Q f ≈ 17
mL/min is predicted to provide a PBS clearance of only
1.5 mL/min. Because volumes of distribution for proteinbound solutes have not been measured, it is not pos
sible to compare the theoretic effects of intermittent
and continuous treatment on plasma solute concentra
tions. Lesaffer et al [11] found that the concentrations
of two solutes which are approximately 90% albumin
bound fell much less than the concentration of urea dur
ing hemodialysis treatment in vivo. If albumin-bound so
lutes were restricted largely to the plasma space, their
concentration would fall rapidly during dialysis despite
the restriction imposed on clearance by albumin binding.
The ﬁnding of Lesaffer et al [11] thus suggests that the
volumes of distribution for protein-bound solutes may
be considerably larger than the plasma volume, in which
case CVVH with Q f ≈ 17 mL/min would lower plasma
protein-bound solute concentrations less effectively than
intermittent dialysis performed 4 hours every other day.
As further shown in Table 4, the predicted clearance of
unbound and bound solutes during CVVH treatment will
increase approximately in proportion if the ultraﬁltration
rate is increased to the recently recommended level of 35
mL/kg/hour, or about 40 mL/min for an averaged size
person [29]. Similar clearances of bound solutes would
be achieved by shifting to CVVHDF and providing the
same total amount of ﬂuid with half used as replacement
ﬂuid and half used as dialysate.
The restriction on the clearance of bound solutes rel
ative to unbound solutes can be overcome only by using
higher dialysate ﬂows and larger kidneys than are now
commonly employed for CVVHDF, as further summa
rized in Table 4. When high dialysate ﬂows are employed,
the clearance of small molecules is accomplished almost
entirely by diffusion and ultraﬁltration serves only to in
crease the clearance of large molecules. The predicted
dependence of protein-bound solute clearances on
dialysate ﬂow and kidney size will be the same when in
termittent treatment is prescribed. Recent studies have

described the treatment of acute renal failure using
hemodialysis for 8 to 12 hours daily [30, 31]. These “low
efﬁciency” regimens often restrict the clearance of urea
and other small unbound solutes by limiting the dialysate
ﬂow rate [31]. Our model predicts that the clearance of
protein-bound solutes would be greater if the clearance
of unbound solutes were restricted by limiting the blood
ﬂow rate while maintaining a higher dialysate ﬂow. For
instance, as summarized in Table 4, the predicted clear
ance of a 90% protein-bound solute would be 10 mL/min
during low efﬁciency dialysis with Q b ≈200 mL/min and
Q d ≈ 100 mL/min and 18 mL/min during low efﬁciency
dialysis with Q b ≈ 100 mL/min and Q d ≈ 200 mL/min,
while both regimens would provide nearly the same urea
clearance.
Several limitations of the current study should be ac
knowledged. We have assumed that solute dissociation
from albumin is rapid compared to the plasma transit time
through the kidney. The efﬁcient extraction of protein
bound solutes by the kidney suggests that this is indeed of
ten the case, but measured dissociation rates are generally
not available. Our model also assumes thorough solute
mixing in both the plasma and the ultraﬁltrate/dialysate
compartments. To the extent that mixing is not complete,
the assumption that kidneys can be characterized by sin
gle K o A values is not justiﬁed, and measured clearances
will fall below predicted values. The magnitude of this
error may be expected to increase when kidneys are em
ployed using ﬂow rates for which they were not designed.
In addition, the K o A values we used in modeling were
obtained from measurements of clearance from albuminfree solutions, and may have exceeded the K o A values
obtained when kidneys were perfused with 4% albumin
[32, 33].
Despite these limitations, the current model accurately
predicted the extent to which clearances of proteinbound solutes are restricted during hemoﬁltration and
hemodiaﬁltration in vitro. Further studies are obviously
required to determine whether the model predicts the
behavior of protein-bound solutes in vivo. It should be
noted that numerous solutes may compete for protein
binding sites in uremic patients. The fractions of vari
ous solutes which are bound to protein may therefore
increase unpredictably as solute concentrations fall dur
ing treatment. In general, clearance values would be ex
pected to decline as protein-binding increases, but this
requires testing in practice. A further interesting possi
bility is that some uremic solutes bind to other blood
constituents such as lipids or red cells in vivo. If binding
is rapidly reversible, such solutes, like protein-bound so
lutes, might be effectively cleared by the normal kidney
but poorly cleared by hemoﬁltration.
To the extent that they apply in vivo, our ﬁndings sug
gest that conventional CVVH and CVVHDF regimens
provide limited clearance of protein-bound solutes. Clin
ical studies, as far as we are aware, have yet to exam

ine this issue. A recent clinical study has shown that ad
dition of hemoﬁltration at rates of 5 to 15 L per hour
increases p-cresol clearance in patients receiving inter
mittent hemodialysis [34]. The current model predicts this
effect, but suggests that increases of the same magnitude
could be more easily achieved by increasing dialysate
ﬂow rate and dialyzer size. A broader question is whether
the clearance of protein-bound solutes is clinically impor
tant. Increasing evidence, however, links protein-bound
solutes to uremic toxicity [6]. Limited clearance of such
solutes could explain, at least in part, why the improved
clearance of large solutes obtained with ultraﬁltration
based therapies has so far not been associated with a dis
cernable improvement in patient outcome [35–37]. Clin
ical studies of modalities which increase protein-bound
solute clearances will be required to address this ques
tion.

APPENDIX
fc =
c(c − 1)(1 − f ) − (q + 1)c f (c f − c + 1) +

[c(1 − c)(1 − f ) + (q + 1)c f (c f − c + 1)]2 + 4(q + 1)c3 f (c f − c + 1)(1 − f )
2c2 (1 − f )

(equation 10)
where c = C p /C alb and q = Q r /Q p .
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